David Shook - 21 Aug 2024 Form 4 Insider Report for Nkarta, Inc. (NKTX)

Role
Chief Medical Officer, Head of Research & Development
Signature
/s/ Alicia Hager, as Attorney-in-Fact
Issuer symbol
NKTX
Transactions as of
21 Aug 2024
Net transactions value
-$6,909
Form type
4
Filing time
23 Aug 2024, 16:30:04 UTC
Previous filing
31 Jul 2024
Next filing
07 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NKTX Common Stock Award $6,909 -1,352 -0.97% $5.11 138,593 21 Aug 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares sold to satisfy tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units and does not represent a discretionary transaction by the Reporting Person.
F2 Includes 2,000 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on May 31, 2024.

Remarks:

Chief Medical Officer, Head of Research & Development